Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced that Co-Founder Robert Langer, Sc.D., will be making the Closing Keynote Address at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), to be held June 24-27, 2015 in Stockholm, Sweden. His keynote address will be held during the last plenary session titled Making Tissues and Organs.
“It’s a great honor to be chosen for this speaking engagement. In my talk, I’ll be discussing many exciting advancements that have been made in the field of tissue engineering, and will be highlighting the investigational Neuro-Spinal Scaffold and the great work being done by InVivo,” said Dr. Langer.
“We are thrilled that Bob has decided to highlight us in this closing keynote address. He is involved with many companies in this space, and his decision to feature InVivo during such a large speaking engagement is validating,” said Mark Perrin, InVivo’s Chief Executive Officer and Chairman.
According to the meeting’s website “The ISSCR Annual Meeting provides an opportunity for scientists, clinicians, educators, and industry professionals to share new data, learn from peers, and discover global advances within the stem cell field. With approximately 3000 professionals from 55 countries, the ISSCR 2015 Annual Meeting is the global source of the discoveries that are the basis for treatments of tomorrow.” (Original Source)
Shares of Invivo Therapeutics Holdings Corp closed yesterday at $15.48. NVIV has a 1-year high of $0 and a 1-year low of $0. The stock’s 50-day moving average is $13.57 and its 200-day moving average is $9.83.
On the ratings front, H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on NVIV and a price target of $25, in a report issued on April 20. The current price target represents a potential upside of 61.5% from where the stock is currently trading. According to TipRanks.com, Fein has a total average return of 27.4%, a 71.2% success rate, and is ranked #80 out of 3632 analysts.
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.